Slate Medicines merges with Fulcrum Therapeutics to reach Nasdaq
Money MovesA failed drugmaker becomes the public listing for a $245 million bet on the next migraine target
Yesterday: Slate and Fulcrum announce merger and $245M financingNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated 2 hours agoFulcrum Therapeutics spent two years watching its two lead drugs fail. On August 17, 2026, the shell that remained agreed to merge with Slate Medicines, a privately held migraine startup, in an all-stock deal paired with a $245 million private placement.
The combined company keeps Slate's name, trades under the ticker 'SLTE,' and pours the cash into one experimental antibody meant to prevent migraine by hitting a target the current drug class leaves untouched. Slate's backers will own 95% of the result.
Why it matters
The deal hands a next-generation migraine antibody a public listing and $245 million to challenge today's CGRP drugs, which don't work for everyone.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Timeline
Order five events from this story, oldest at top. Each in the right slot scores 1 — neighbours within one slot count too. Your previous result — green ✓ for exact slots, yellow ~ for off by one. Cards now in true chronological order.
Sign up to save your score and track a streak across stories.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
A Boston migraine startup developing antibodies against the PACAP/VIP pathway.
A public biotech that lost both lead drugs and became a listing vehicle for Slate.
The healthcare investor leading Slate's financing round.
Timeline
September 2024 August 2026
-
Slate and Fulcrum announce merger and $245M financing
Latest MergerThe two firms agree to an all-stock reverse merger paired with a $245 million placement. The combined company trades as 'SLTE' and is funded into 2029.
-
Fulcrum drops its second drug
CorporateFulcrum discontinues pociredir for sickle cell disease after FDA safety concerns and opens a review of strategic options.
-
Rival anti-PACAP drug posts positive data
ClinicalLundbeck reports positive Phase 2b results for bocunebart, its own anti-PACAP migraine antibody, validating the target Slate is chasing.
-
Slate Medicines launches
FinancingSlate emerges from RA Capital's incubator with a $130 million Series A to develop anti-PACAP antibodies for migraine prevention.
-
Fulcrum's lead drug fails Phase 3
ClinicalLosmapimod misses its goals in a muscular dystrophy trial. Fulcrum's stock falls about 70% in a day, from $8.85 to $2.60.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
Aimovig and the CGRP migraine revolution (2018)
The FDA approved Aimovig (erenumab) from Amgen and Novartis, the first drug designed specifically to prevent migraine by blocking CGRP, a signaling molecule in the brain. Emgality, Ajovy, and Vyepti followed within two years.
A class of injectable antibodies gave millions of patients a preventive option that older repurposed pills could not match.
CGRP drugs grew into a multibillion-dollar market, but a large share of patients still respond poorly or not at all.
Slate is betting the next gains come from PACAP, a separate pathway, for the patients CGRP drugs leave behind.
Aduro Biotech's reverse merger into Chinook (2020)
Aduro Biotech, a public company whose cancer immunotherapy programs had stalled, merged with privately held Chinook Therapeutics, which developed kidney-disease drugs. Chinook took over the public listing and Aduro's cash.
The deal gave Chinook a Nasdaq listing without a traditional IPO and refocused the company on new science.
Novartis acquired Chinook in 2023 for up to $3.5 billion, one of the more successful biotech reverse mergers.
It is the template for this deal: a failed public biotech becomes the vehicle for a well-funded private company's science.
Lundbeck's anti-PACAP proof of concept (2023)
Lundbeck's antibody Lu AG09222 cut migraine days versus placebo in a mid-stage trial, with results later published in the New England Journal of Medicine. It was the first clinical proof that blocking PACAP could prevent migraine.
The data validated PACAP as a real drug target, distinct from CGRP.
Lundbeck advanced the drug, now called bocunebart, into a larger Phase 2b program that read out positively in 2026.
Slate's whole thesis rests on this mechanism; Lundbeck both proves it works and is the company to beat.
